Feb 24, 2026Polyphenol Stack Synergy: Quercetin, Resveratrol, Curcumin, and EGCG Combined EvidenceQuercetin, resveratrol, curcumin, and EGCG activate overlapping pathways — NRF2, SIRT1, AMPK, and NFkB inhibition. Stacking them is popular but evidence for synergistic human benefit is largely extrapolated from in vitro and animal models. This article assesses what stacking adds and what it does not.
Feb 19, 2026Resveratrol and Memory Retention: Evidence from a 26-Week Randomized Trial in Older AdultsWitte et al. (2014) found statistically significant memory improvements in adults 50–75 taking 200 mg/day resveratrol for 26 weeks, alongside improved hippocampal connectivity and glucose metabolism. Sample size was small (n=46) and findings require replication.
Feb 19, 2026Polyphenol Protocols in Cognition Clinics: Clinical Context and Evidence LimitsResveratrol, quercetin, and fisetin are used in some cognition-focused protocols, but human evidence is mixed and best interpreted as adjunctive support rather than primary therapy.
Feb 11, 2026Pterostilbene vs Resveratrol: Bioavailability, Sirtuin Activation, and Evidence ComparisonPterostilbene is a methylated resveratrol analog with substantially better oral bioavailability. It activates SIRT1 and AMPK, lowers blood pressure in some trials, but has fewer published human studies than resveratrol. The trade-off between bioavailability and evidence depth is real.
Feb 10, 2026Exercise Mimetics: Can Supplements Replace Movement? AICAR, Resveratrol, and Irisin EvidenceExercise produces benefits through AMPK activation, BDNF upregulation, and irisin release that no supplement fully replicates. Some compounds (resveratrol, AICAR) partially activate overlapping pathways in animals. Human evidence for exercise replacement is weak. This article separates marketing from mechanism.
Feb 10, 2026Resveratrol Protocols in Longevity Clinics: Evidence, Dosing, and Safety ContextHow longevity clinics structure resveratrol protocols and what current human evidence does and does not support.
Feb 4, 2026Resveratrol and SIRT1: Longevity Pathway Activation, Human Trial Disappointments, and ContextResveratrol activated enormous interest as a SIRT1 activator after early animal data. Human trials have been largely disappointing for longevity endpoints. Benefits in specific metabolic contexts (glucose tolerance, inflammation) are more supported. Understanding the gap between mechanism and human outcome is essential.